Despite a share price drop, Shanghai Rendu Biotechnology's P...
Despite a share price drop, Shanghai Rendu Biotechnology's P/S ratio is still high compared to industry peers, raising concerns due to its recent poor growth rate. If current medium-term revenue trends persist, it could significantly affect the share price, posing a risk to shareholders and potential investors.
Shanghai Rendu Biotechnology Co., Ltd.'s (SHSE:688193) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment